Cisplatin, Carboplatin With Pemetrexed Acceptable in Patients With NSCLC

Share this content:
Cisplatin or carboplatin in combination with pemetrexed for non-small cell lung carcinoma demonstrated acceptable safety-related feasibility.
Cisplatin or carboplatin in combination with pemetrexed for non-small cell lung carcinoma demonstrated acceptable safety-related feasibility.

Cisplatin or carboplatin in combination with pemetrexed as adjuvant treatment for patients with completely resected stage 1b/2 non-small cell lung carcinoma demonstrated acceptable safety-related feasibility and tolerability, according to a study published online ahead of print in the journal Lung Cancer.1

In this multicenter, open-label, parallel-group, non-comparative phase 2 study, a total of 118 patients were treated with either pemetrexed (500 mg/m2) + cisplatin (75 mg/m2) or carboplatin (AUC5) for 4 cycles of 21 days. A total of 71.9% (46/64) of patients in the pemetrexed + cisplatin group and 88.9% (48/54) of patients in the pemetrexed + carboplatin group completed 4 cycles.

The study's primary endpoint s were: treatment feasibility defined as 4 cycles completed with no cycle delay > 42 days and ≤ 2 dose reductions and no grade ≥ 3 toxicities at a follow-up of 30 days after last drug administration. Secondary endpoints were overall survival and safety.

Results showed that the study failed to meet the primary endpoint of feasibility (> 60% of patients). A total of 59.4% of patients in the cisplatin group (95% CI, 46.4 – 71.5) and 50% of patients in the carboplatin group (95% CI, 36.1 – 63.9).

RELATED: Nedaplatin Plus Docetaxel May Be New Treatment for Squamous Cell Lung Cancer

A post-hoc analysis considering only safety revealed feasibility in 81.3% (95% CI, 69.5 – 89.9) of patients in the cisplatin group and 90.7% (95% CI, 79.9 – 96.9) of patients in the carboplatin group.

Overall survival rates for both groups were 82% to 83% after 3 years and 80% to 83% after 5 years.

In regard to safety, treatment-related grade ≥ 3 adverse events were experienced by approximately 30% in each group.

Reference

  1. Schmid-Binder G, Engel-Riedel W, Reck M, et al. A randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB of II non-small-cell lung cancer [published online ahead of print November 7, 2015]. Lung Cancer. doi: 10.1016/j.lungcan.2015.11.007.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs